Case Report

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients

Stephanie Du Four, Angela Hong, Matthew Chan, Michail Charakidis, Johnny Duerinck, Sofie Wilgenhof, Wei Wang, Linda Feng, Alex Michotte, Meena Okera, Brindha Shivalingam, Gerald Fogarty, Richard Kefferd, and Bart Neyns

1 Neurosurgery, UZ Brussel, Campus Jette, Laarbeeklaan 101, 1090 Brussels, Belgium
2 Medical Oncology, UZ Brussel, Campus Jette, Laarbeeklaan 101, 1090 Brussels, Belgium
3 Melanoma Institute Australia, Poche Centre, 40 Rocklands Road, Sydney, NSW 2060, Australia
4 Medical Oncology, Royal Darwin Hospital, 105 Rocklands Drive, Tiwi, Darwin, NT 0810, Australia
5 Radiation Oncology, University of Sydney, Edward Ford Building, Physics Road, Camperdown, Sydney, NSW 2006, Australia
6 Westmead Clinical School, University of Sydney, Cnr Hawkesbury Road & Darcy Road, Westmead, NSW 2145, Australia
7 Neuropathology, UZ Brussel, Campus Jette, Laarbeeklaan 101, 1090 Brussels, Belgium
8 Department of Neurosurgery, Mater Hospital, 25 Rocklands Road, Crows Nest, NSW 2060, Australia
9 Department of Radiation Oncology, Mater Hospital, 25 Rocklands Road, Crows Nest, NSW 2060, Australia

Correspondence should be addressed to Gerald Fogarty; gerald.fogarty@cancer.com.au

Received 26 March 2014; Revised 26 May 2014; Accepted 16 June 2014; Published 1 July 2014

Academic Editor: Y. Yamada

Copyright © 2014 Stephanie Du Four et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Four cases previously treated with ipilimumab with a total of six histologically confirmed symptomatic lesions of RNB without any sign of active tumour following stereotactic irradiation of MBM are reported. These lesions were all originally thought to be disease recurrence. In two cases, ipilimumab was given prior to SRT; in the other two ipilimumab was given after SRT. The average time from first ipilimumab to RNB was 15 months. The average time from SRT to RNB was 11 months. The average time from first diagnosis of MBM to last follow-up was 20 months at which time three patients were still alive, one with no evidence of disease. These cases represent approximately three percent of the total cases of melanoma and ten percent of those cases treated with ipilimumab irradiated in our respective centres collectively. We report this to highlight this new problem so that others may have a high index of suspicion, allowing, if clinically warranted, aggressive surgical salvage, possibly resulting in increased survival. Further studies prospectively collecting data to understand the denominator of this problem are needed to determine whether this problem is just the result of longer survival or whether there is some synergy between these two modalities that are increasingly being used together.

1. Introduction

Melanoma brain metastases (MBMs) are common and can impact quality of life and mortality, especially through a tendency to hemorrhage [1]. Historically, MBM confers a poor prognosis, with a median overall survival of less than 6 months [2]. Radiation is often employed and stereotactic radiosurgery (SRS) or stereotactic radiation therapy (SRT)
is increasing following a positive randomized clinical trial (RCT) [3]. Radiation necrosis of the brain (RNB) is a well-known late toxicity of SRS. Given the dismal prognosis of patients with MBM, RNB has not previously been of major concern [4, 5].

Ipilimumab in melanoma is being increasingly used following RCTs demonstrating increased survival [6–8]. Controlling MBMs is therefore even more important. We recently published RNB in the scenario of three patients with MBM exposed to ipilimumab and SRS from a single institution [9] but only one had histologically confirmed RNB. This report is of four additional cases from multiple institutions that developed symptomatic RNB that was histologically confirmed.

2. Materials and Methods

2.1. Case 1. A 50-year-old male was treated with ipilimumab (3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of 4 administrations) for stage four disease 5 years after his primary diagnosis, resulting in disease stabilization. Two years later, reinduction of ipilimumab (3 mg/kg administered intravenously over 90 min every 3 weeks for a total of four administrations) was offered because of progression. A year later a new solitary right MBM (Figure 1(a)) was treated with SRS (1 fraction of 20 Gray (Gy)) with response over 6 months (Figure 1(b)). Treatment with the BRAF inhibitor dabrafenib was initiated at a dose of 150 mg twice daily for progression with extracranial disease that had a positive BRAF mutation.

Ten months later the brain lesion progressed (Figure 1(c)), accompanied by increasing headache and confusion without any other disease progression. RNB was suspected and treatment with methylprednisolone (32 mg, bid) and valproic acid (500 mg, bid) was initiated. Symptoms and perilesional oedema persisted at two months after the initiation of corticotherapy (Figure 2(a)). A neurosurgical resection confirmed the diagnosis of RNB (Figures 2(b) and 2(c)–2(f)). Eighteen months later the patient remains in complete remission on dabrafenib treatment.

2.2. Case 2. A 29-year-old man with stage four BRAF V600E positive disease had a solitary MBM in the left frontal lobe (Figure 3(a)) treated with surgery. Four months later, two new left frontal brain metastases had WBRT (30 Gy, 10 fractions) with a SRT boost (45 Gy in 10 fractions) (Figure 3(b) shows the first lesion at that time). Two months later ipilimumab was initiated (3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of four administrations). Four months later, a recurrent left frontal and new parietal lobe brain metastasis were treated with SRS (18 Gy in one fraction) (Figure 3(c)). Seven months later he developed headaches. Histology of the left frontal lobe metastases showed RNB (Figure 3(d)). At last follow-up six months later he then had progression.

2.3. Case 3. A 62-year-old man with unknown primary wild type BRAF metastatic melanoma had symptoms with three MBMs in the left temporal lobe, precentral gyrus, and frontal lobe treated with SRT (40 Gy in 8 fractions) [10, 11]. Three months later progressive extracranial disease was treated with ipilimumab (3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of four administrations). Six months later he presented with seizures and dysarthria, which were caused by an increase in the temporal lesion. Neurosurgical histology showed RNB. One month later he developed a right hemiparesis due to an increase in size of the lesion localized in the left precentral gyrus. Histology
showed RNB. Six months later, sixteen months after the initial SRT, he re-presented with a worsening right hemiparesis due to a recurrence of the left precentral gyrus lesion. Histology revealed RNB. The patient died postoperatively from pulmonary embolus.

2.4. Case 4. Two years after a BRAF wild type primary diagnosis, a 72-year-old man had a lung and three brain metastases in right frontoparietal, left parietal lobe, and left cerebellar hemisphere locations treated with WBRT (30 Gy in 10 fractions) with simultaneous integrated boost (45 Gy in 10 fractions). Histopathological examination indicating (c) tissue necrosis and fibrinoid necrosis of small blood vessels (Hematoxylin and Eosine (H&E) staining, ×200); (d) H&E staining (×400); (e) radionecrosis surrounding gliosis and inflammatory cell reaction (H&E staining, ×200); and (f) focal infiltration of inflammatory cells and subpial gliosis (H&E, staining ×400).
fractions) in a RCT. Three months later, ipilimumab was initiated (3 mg/kg or 10 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of four administrations) to treat progressing extracranial disease. Fourteen months after RT he developed a headache and gait disturbance, with MRI showing enlargement of the right frontoparietal lesion. Neurosurgical resection showed RNB (Figure 4).

3. Results and Discussion

The results are summarised in Table 1. We report on four cases previously treated with ipilimumab with a total of of six histologically confirmed symptomatic lesions of RNB without any sign of active tumour following stereotactic irradiation of MBM. These lesions were all originally thought to be disease recurrence. The average time from first ipilimumab to RNB was 15 months. The average time from SRT to RNB was 11 months. In two cases ipilimumab was given prior to SRT, and in the other two ipilimumab was given after SRT. The average time from first diagnosis of MBM to last follow-up was 20 months at which time three patients were still alive, one with no evidence of disease. These cases represent approximately three percent of the total cases of melanoma and ten percent of those cases treated with ipilimumab irradiated in our respective centres collectively during the eight years of collection of these cases. We report this to highlight this new problem so that others may have a high index of suspicion, allowing aggressive surgical salvage if clinically warranted.
Table 1: Overview of the clinical history of the four patients.

| Patient | 1 | 2 | 3 | 4 | Average months |
|---------|---|---|---|---|----------------|
| MBM number | 1 | 3 | 4 | 3 |                |
| MBM with RNB | 1 | 1 | 3 | 1 |                |
| Dose of ipilimumab (mg/kg) | 3 | 3 | 3 | Blinded* |                |
| Reinduction of ipilimumab | Yes | No | No | No |                |
| Type of RT | SRS | SRS + WBRT | SRT | SRT + WBRT |                |
| Stereotactic radiation dose (total dose Gy/#) | 20/1 | 18/1 | 40/8 | 45/10 |                |
| BRAF treatment before RNB | Yes | Yes | No | No |                |
| Time from first ipi to RNB (months) | 46 | 11 | 6, 7, 13 | 11 | 94/6 = 15 |
| Time from SRT to RNB (months) | 10 | 7 | 9, 10, 16 | 14 | 66/6 = 11 |
| Further intracranial progression at last FU | No | Yes | No | No |                |
| Status at last FU; months following first diagnosis of MBM | NED at 28 | PD at 23 | DONC at 16 | PD at 14 | 81/4 = 20 |

Figure 4: Histopathologic examination indicating (a) an area of infarction (H&E staining, ×10) and (b) a transitional zone showing ischemia (H&E staining, ×20).

These four additional cases with RNB are of particular interest because RNB was histopathologically confirmed. In these cases, there was no marked infiltration of the resected tissue by inflammatory cells. This is different from the case reported by Hodi et al. [12] who documented marked infiltration by lymphocytes and macrophages in a resected MBM following SRS and ipilimumab treatment. Infiltration of melanoma metastases with immune cells (predominantly CD4+ and CD8+ T-cells) is a hallmark of the cellular response to ipilimumab treatment in responding patients. Such infiltration by immune cells can lead to an initial increase in the dimensions of the lesion, followed by regression. In our cases, high-dose corticotherapy preceding the resection of the lesion might have attenuated the inflammatory infiltrate. However, the absence of a symptomatic response to steroids and the fact that in the first case a nearly complete regression preceded progression of the lesion make it highly unlikely that an infiltration by immune cells was responsible for symptomatic progression.

The improved survival of patients responding to ipilimumab may place them at increased risk for developing late sequelae from treatment such as RNB. Peak incidence of RNB is around 12–15 months after radiotherapy. At 16–22 Gy, RNB can occur in up to 50% of treated lesions. For SRT the most important predictive variables include dose, tumour volume, and location of the lesion. The pathophysiological cascade that results in RNB consists of a series of inflammatory events, which leads to extracellular oedema, loss of neurons covered with myelin, and eventually hypoxia and necrosis [13–15].

Further studies prospectively collecting data to more exactly understand the denominator of this problem are needed to determine whether this problem is just the result of longer survival or whether there is some synergy between these two modalities that are increasingly being used together. The diagnosis and treatment of patients with new lesions in the brain, when successfully treated with SRS and immune therapies for melanoma, need to be approached with a high index of suspicion for RNB. Survival of these patients may be increased beyond that normally seen in MBMs by aggressive surgical salvage.

4. Conclusions

Four cases previously treated with ipilimumab with a total of six histologically confirmed symptomatic lesions of RNB
without any sign of active tumour following stereotactic irradiation of MBM are reported. These lesions were all originally thought to be disease recurrence. The average time from first ipilimumab to RNB was 15 months. The average time from SRT to RNB was 11 months. The average time from first diagnosis of MBM to last follow-up was 20 months at which time three patients were still alive, one with no evidence of disease. These cases represent approximately three percent of the total cases of melanoma and ten percent of those cases treated with ipilimumab irradiated in our respective centres collectively during the eight years of collection of these cases. We report this to highlight this new problem so that others may have a high index of suspicion, allowing, if clinically warranted, aggressive surgical salvage, possibly resulting in increased survival.

**Abbreviations**

- MBM: Melanoma brain metastasis
- SRS: Stereotactic radiosurgery
- SRT: Stereotactic radiotherapy
- WBRT: Whole brain radiotherapy
- RNB: Radionecrosis of brain
- FU: Follow-up
- NED: No evidence of disease
- PD: Progressive disease
- DONC: Died of neurosurgical complications
- RCT: Randomised controlled trial
- Gy: Gray
- #: Radiotherapy fraction; either 3 or 10 mg/kg on RCT.

**Conflict of Interests**

Richard Kefford has a conflict of interests with BMS (institutional reimbursement for Advisory Boards BMS). All other authors have no conflict of interests.

**Acknowledgment**

The authors are thankful to Cancer Australia, Department of Health and Aging, for their ongoing support of the ANZMTG 01.07 WBRT in melanoma trial.

**References**

1. [1] J. H. Sampson, J. H. Carter Jr., A. H. Friedman, and H. F. Seigler, “Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma,” *Journal of Neurosurgery*, vol. 88, no. 1, pp. 11–20, 1998.

2. [2] E. Fonkem, E. J. Uhlmann, S. R. Floyd et al., “Melanoma brain metastasis: overview of current management and emerging targeted therapies,” *Expert Review of Neurotherapeutics*, vol. 12, no. 10, pp. 1207–1215, 2012.

3. [3] D. W. Andrews, C. B. Scott, P. W. Sperduto et al., “Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial,” *The Lancet*, vol. 363, no. 9422, pp. 1663–1672, 2004.

4. [4] M. Kocher, R. Soffietti, U. Abacioglu et al., “Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study,” *Journal of Clinical Oncology*, vol. 29, no. 2, pp. 134–141, 2011.

5. [5] M. Tsao, W. Xu, and A. Sahgal, “A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases,” *Cancer*, vol. 118, no. 9, pp. 2486–2493, 2012.

6. [6] P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” *New England Journal of Medicine*, vol. 364, no. 26, pp. 2507–2516, 2011.

7. [7] G. V. Long, U. Trefzer, M. A. Davies et al., “Dabrafenib in patients with V600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial,” *The Lancet Oncology*, vol. 13, no. 11, pp. 1087–1095, 2012.

8. [8] K. T. Flaherty, C. Robert, P. Hersey et al., “Improved survival with MEK inhibition in BRAF-mutated melanoma,” *The New England Journal of Medicine*, vol. 367, no. 2, pp. 107–114, 2012.

9. [9] S. du Four, S. Wilgenhof, J. Duerinck et al., “Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies,” *European Journal of Cancer*, vol. 48, no. 16, pp. 3045–3051, 2012.

10. [10] R. Awd, F. Gogarty, A. Hong et al., “Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases—the first Australian experience,” *Radiation Oncology*, vol. 8, no. 1, article 62, 2013.

11. [11] G. Rodrigues, S. Yartsev, B. Yaremko et al., “Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases,” *International Journal of Radiation Oncology, Biology, Physics*, vol. 80, no. 4, pp. 1128–1133, 2011.

12. [12] F. S. Hodi, D. A. Oble, J. Drappatz et al., “CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS,” *Nature Clinical Practice Oncology*, vol. 5, no. 9, pp. 557–561, 2008.

13. [13] G. Minniti, E. Clarke, G. Lanzetta et al., “Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis,” *Radiation Oncology*, vol. 6, no. 1, p. 48, 2011.

14. [14] S. Telaere, A. Fabi, A. Pace et al., “Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease,” *Journal of Neuro-Oncology*, vol. 113, no. 2, pp. 313–325, 2013.

15. [15] C. Matuschek, E. Bölke, J. Nawatny et al., “Bevacizumab as a treatment option for radiation-induced cerebral necrosis,” *Strahlentherapie und Onkologie*, vol. 187, no. 2, pp. 135–139, 2011.